The systemic immune inflammation index is a reliable and novel risk factor for metabolic dysfunction-associated fatty liver disease

These findings suggest that SII could serve as a useful, noninvasive marker for diagnosing and monitoring MAFLD, warranting further longitudinal studies to explore its role in disease progression and treatment response.